Net Income

A major study reveals dropping MMR vaccination rates and a surge in measles, but identifies a key window for pediatricians to prevent missed immunizations.

Interactive Brokers reports its clients beat the S&P 500 in 2025. We dive into the numbers, the platform's unique advantages, and what this means for you.

Occidental nets $9.7B from its OxyChem sale to Berkshire Hathaway, pivoting to oil and carbon capture while retaining significant environmental liabilities.

Tesla's Q4 report shows a complex picture. Vehicle deliveries fell short, but record-breaking growth in the energy division hints at a major strategic shift.

Principal Financial is set to unveil its 2026 forecast. Investors weigh strong 2025 results against analyst caution and shifting economic tides.

Known for hair styling, Wavytalk is launching a clinically-tested LED mask. Can this at-home device truly rival professional skincare treatments?

The specialty insurer's acquisition of Apollo is set to add over $1.5B in managed premiums, provide a strategic entry into Lloyd's, and boost tech.

Investors eye Hexcel's Q4 2025 results for signs of an aerospace rebound, strategic shifts under new leadership, and the future of advanced composites.

New ETFs boast yields up to 99%, but a closer look at their complex options strategy reveals significant risks of capital erosion for unwary investors.

Fintech pioneer Currenc Group divests its payments hub Tranglo in a $400M deal, fueling a bold transformation into AI, Web3, and digital assets.

Genelux appoints Dr. Jason Litten as CMO, a strategic move to steer its promising oncolytic virus, Olvi-Vec, through crucial late-stage cancer trials.

Hoth Therapeutics files patents for a therapy to mitigate severe skin reactions from cancer treatments, a strategic move that could transform patient care.

BridgeBio Pharma hosts a key investor webinar on its oral drug infigratinib for achondroplasia, setting the stage for crucial trial results in Q1 2026.

As robotaxis and self-driving trucks go commercial, a new group from Seeing Machines aims to solve the critical human trust and safety challenge.

Fresh off a major drug approval, Insmed's upcoming J.P. Morgan talk is under scrutiny as investors eye pipeline updates and acquisition potential.

A price increase on critical specialty chemicals by Trecora reveals mounting cost pressures that could ripple through automotive, construction, and water treatment.

RPM International's 52nd straight year of dividend hikes cements its 'Dividend King' status. We look at the strategy behind this rare achievement.

Following the sale of its legacy business, the newly-rebranded Accendra Health launches on the NYSE with a laser focus on the booming home healthcare market.

Smart cart maker A2Z Cust2Mate pivots for hyper-growth as its visionary founder exits, leaving the CEO as interim chair to steer a global expansion strategy.

Bitcoin miner Bitfarms sells its last Latin American asset for $30M, pivoting fully to the booming North American AI and HPC infrastructure market.